monoclonal antibody against ciap1 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
85
Structured Review
R&D Systems
monoclonal antibody against ciap1
Monoclonal Antibody Against Ciap1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/monoclonal+antibody+against+ciap1/Human+cIAP-1%2FHIAP-2+Antibody/pmc04196171-139-21-26
Average 85 stars, based on 8 article reviews
Monoclonal Antibody Against Ciap1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/monoclonal+antibody+against+ciap1/Human+cIAP-1%2FHIAP-2+Antibody/pmc04196171-139-21-26
Average 85 stars, based on 8 article reviews
monoclonal antibody against ciap1 - by Bioz Stars,
2026-09
85/100 stars
Images
1) Product Images from "The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis"
Article Title: The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis
Journal: Oncotarget
doi:
Figure Legend Snippet: (A) Correlation of immunohistochemical staining intensity of BIRC6 and clinical (T) stages of prostate cancer (mean staining intensity ± S.E.M.). (B-D) Correlation of BIRC6 immunohistochemical staining intensity with the absence and presence of poor prognostic factors, such as recurrence of PSA, lymph node metastasis and prostatic capsule invasion. The statistical significance of positive trends was determined by the Chi square test for trend. (E) Representative images of correlated expressions between BIRC6 and survivin, XIAP and cIAP1. 20x magnification, scale bar, 100 μm.
Techniques Used: Immunohistochemical staining, Staining
Figure Legend Snippet: (A-B) Western blotting showing protein levels of BIRC6, cIAP1 and survivin in two CRPC cell lines (A) PC-3 cells and (B) C4-2 cells transfected with Mock or increasing dosages of scrambled ASO (Scrb), dASOs 6w2 and 6w5 for 72 hr. (C) Comparison of dual IAP targeting and single IAP-targeting. Cell viability of PC-3 cells transfected with dASOs 6w2, 6w5 and siRNA-targeting BIRC6, cIAP1 or survivin, was determined by MTS assay at 72 hr after transfection. Cell viabilities of ASO- and siRNA-treated cells were normalized with corresponding Scrb ASO and siRNA controls. Error bars represent mean percentage cell viability ± S.D. Western blotting of 3 IAPs showing comparable amounts of reduced protein expression obtained with dASO and siRNA single IAP-targeting. (D) Proliferation of PC-3 cells transfected with mock, Scrb ASO, dASOs 6w2 and 6w5. Error bars represent mean cell number ± S.D. (E) MTS viability assay of C4-2 cells treated with dASOs.
Techniques Used: Western Blot, Transfection, Comparison, MTS Assay, Expressing, Viability Assay
Related Articles
Immunohistochemical staining:Article Title: The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis Article Snippet: .. Immunohistochemical staining using rabbit polyclonal antibody against BIRC6 (NB110-40730, Novus Biological, 1:50), rabbit monoclonal antibody against Survivin (#2808, Cell Signaling, 1:50), Staining:Article Title: The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis Article Snippet: .. Immunohistochemical staining using rabbit polyclonal antibody against BIRC6 (NB110-40730, Novus Biological, 1:50), rabbit monoclonal antibody against Survivin (#2808, Cell Signaling, 1:50), Solvent:Article Title: The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis Article Snippet: .. Immunohistochemical staining using rabbit polyclonal antibody against BIRC6 (NB110-40730, Novus Biological, 1:50), rabbit monoclonal antibody against Survivin (#2808, Cell Signaling, 1:50), |